ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.
Company Details
- Employees
- 2
- Founded
- -
- Address
- La Petite Halle, 31 Rue Gustave Eiffel, Grenoble,38000,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.alpionertx.com/
- HQ
- Grenoble
Alpioner Therapeutics Questions
Alpioner Therapeutics's website is http://www.alpionertx.com/
Alpioner Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/alpionertx
Alpioner Therapeutics has
2 employees.
View email and phone details for 2
employees at Alpioner Therapeutics.
Alpioner Therapeutics's industry is
Biotechnology Research
Alpioner Therapeutics's top competitors are
Ais Biotech,
Upmem,
Huntx Pharma,
The Element Biotechnology,
Epynext Therapeutics,
Baxiva,
React Therapeutics,
Xpdeep,
Apy Therapeutics, Llc,
Dillico.
Alpioner Therapeutics's categories are Biotechnology Research
Alpioner Therapeutics's founding year is 2023
